Samarkand Group PLC - Annual Results FY24 and Update on Future Strategy
Samarkand Group plc
("Samarkand", the "Company" or together with its subsidiaries the "Group")
Full year results FY24, Update on Future Strategy, Share Option Grant
Samarkand Group plc, (AQSE:SMK), the consumer brand owner and cross border eCommerce distribution services group announces full year results for the year ended
FY24 Financial highlights
· Revenue decreased by 3% to
§ Brand Ownership revenues increased 16% to
§ Brand Acceleration revenue decreased 18% to
§ Distribution revenues increased 13% to
· Gross margin increased from 55% to 60%.
· Adjusted EBITDA* loss decreased by 60% to
· Net loss after taxation increased by 4.3% to
· Q4 adjusted EBITDA loss was
· Cash and cash equivalents at
· Owned brands, Napiers the Herbalists and
· Sales of third-party brands in
· The independent auditor's reports on the Annual Report and Accounts for the year ended
FY24 Strategic and operational highlights
· Significant reduction in adjusted EBITDA losses compared to prior year as a result of adjustments to the Group's cost base and an improvement in gross profit margins as the Group focuses on its core activities and its goal of moving the Group into profitability.
· Strong growth in Brand Ownership year over year which has contributed to improving gross margins and reduction in losses as well as reducing the Group's dependency on the Chinese market. Brand Ownership now accounts for c46% of Group revenues
· Our portfolio of owned consumer brands has maintained strong momentum with revenues increasing 16% compared to last year. Napiers the Herbalists, a natural herbal health and wellness brand and
· Brand Ownership growth was generated by product quality and packaging upgrades, new product development, marketing enhancements, development of social commerce channels, successful launch into the
· Napiers the Herbalists run rate revenues are in the range of
· Recognising the changing market dynamics in
· Investment in Nomad Checkout solution was withdrawn in the year as a result of insufficient market traction from merchants and logistics partners. In the current operating environment, the Group does not see the conditions for sustainable commercialisation of this offering therefore, an impairment charge of
· Continued selective reduction in operating costs as the Group concentrates more of its resources on the most attractive and profitable activities. Key highlights include warehouse relocation to a more cost-effective fit for purpose site and the reduction in Group administrative expenses, before exceptional costs, by 17% when compared to prior year.
Post year end highlights
Q1 FY 25 Trading
· Q1 FY25 revenues were 17% below prior year despite healthy growth in our owned brands and distribution in the
· Q1 adjusted EBITDA loss is estimated to be 27% lower than the prior year despite the reduction in top line revenues.
· Owned brands sales in the
·
Owned Brand Portfolio Adjustments - Acquisition and Disposal
· Acquisition of Optimised Energetics Ltd completed on the
· Disposal of our probiotic brand Probio7 completed on the
· The disposal of Probio 7 enables the Group to increase resources behind our faster growing brands Napiers the Herbalists, our natural herbal apothecary brand and
· Unsecured, unconvertible loans made by the Directors on a bridging basis to enable the acquisition of Optimised Energetics Ltd were repaid on
Strategy Update
· Our strategy has shifted in the course of the last 18 months as the performance of our owned brands primarily in the
· As a result, we increased resources behind our owned brands and adopted a more selective approach to distributing third party brands in
· Our future is as a scale up platform for meaningfully different, high potential, niche brands in the health and healing space, brands targeted at specific consumer segments with long term growth potential, specifically natural herbal health and beauty and fertility and reproductive health
· Our platform offers brands shared sales, marketing, supply chain and logistics and corporate services. Our growth playbook covers innovation and product development, DTC, eCommerce and premium retail sales, social commerce and internationalisation. Our operations playbook includes warehousing and logistics, manufacturing and sourcing services.
· As a scale up platform for niche, founder led, health and wellness brands we see opportunity to invest to accelerate growth in our existing brands and scope for future acquisitions to strengthen our portfolio and add to our platform services.
FY23 Option Grant
As communicated in our FY23 annual report, the Remuneration Committee and the Board approved a bonus payout of 90% to the Executive Directors. The Bonus Scheme was based on the achievement of pre-set Group Financial and Non-Financial Performance Targets for the year ending
To align the executives' interests with those of shareholders, and manage cash costs, 100% of the bonus payable is deferred into Company Share Awards in the form of nil cost options. The number of options to be granted will be determined by the price of the last equity transaction by the Company, which was the open offer in
As the Company has been in a close period since the signing of the Accounts last year, due to the expected Acquisition of Optimised Energetics Ltd and the disposal of Probio 7, the first tranche of the award was not granted after last year's signing of the accounts. The Company will therefore grant both tranches of the bonus options shortly after the signing of the
"I am pleased with the progress being made in shifting the business towards profitability and in defining the future direction of the Group as a scale up platform for high potential, meaningfully different, health and healing brands, anchored in fast growing consumer segments, with the ability to introduce those brands to the Chinese consumer. The disposal of Probio7, the acquisition of Optimised Energetics Ltd and adjustments we are making to our approach to the
Once our goal of moving the Group into profit is secure we will focus on increasing investment behind the scaling of our owned brands and to selectively add to the portfolio in the future through acquisition.
Whilst the underlying value of the Company, in terms of its assets, capabilities and potential, is not currently reflected in the share price, we remain focused on improving the underlying performance of the business, reaching profitability and increasing shareholder value.
We are also delighted to separately announce the appointment of Guild Financial Advisory as our new Corporate Adviser."
A copy of the full accounts will be made available on the Company's website www.samarkand.global
For more information, please contact:
|
Samarkand Global plc |
Via Guild:
http://samarkandglobal/ |
|
Guild Financial Advisory Limited - Corporate Adviser |
T: +44 (0)7973 839767 E: ross.andrews@guildfin.co.uk
T: +44 (0)7834 458 095 |
Notes to Editors
Samarkand is a consumer brand owner and distributor operating a scale up platform for niche, premium, multichannel, health and healing brands. Core owned brands include Napiers the Herbalists,
Founded in 2016, Samarkand is headquartered in Tonbridge,
For further information please visit https://www.samarkand.global/
Chairperson's Statement
I am delighted with the progress being made in Samarkand in shifting the business towards profitability and in defining the future direction of the Group as a scale up platform for niche, differentiated, health and healing brands with the special ability to introduce those brands to the Chinese consumer.
I would like to take this opportunity to thank the entire team for their contribution and commitment, as well as their resilience and adaptability in moving the group forward over the last 12 months, particularly in the face of an increasingly difficult trading environment for international consumer brands in
The momentum behind the Group's portfolio of owned brands is encouraging and the future for those brands looks promising on the basis of the categories, segments and trends which they tap, their differentiated positioning and the agility of the teams that are managing these brands.
The acquisition of Optimised Energetics Ltd and disposal of Probio7 are positive strategic adjustments to the portfolio of owned brands which improve the growth profile of the portfolio and lock in manufacturing flexibility as well as providing the group with some additional working capital to enable it to pursue its strategy.
While
Board and Governance
Our Board which was established at the time of the IPO is operating well, bringing a wealth of experience to the Group I would like to thank my fellow Directors for their service and commitment in the last year in which their guidance to the business has been invaluable.
Summary and Outlook
Samarkand has consistently demonstrated its ability to adapt to changing market conditions and keep moving forward. The shift to focus on the portfolio of owned brands will accelerate the Group's path to profitability. The Group has proven it is able to acquire niche, premium health and healing brands and improve the top and bottom line in those brands. I look forward to seeing further growth and development of the Group's owned brands including the recently acquired Natures Greatest Secret and BeNatural Essentials.
Chairperson
CEO REVIEW
We have made strong progress towards our goal of becoming profitable despite an increasingly challenging trading environment in the Chinese market where consumer confidence remains low, competitive intensity is accelerating and promotional warfare between brands and channels is now the norm.
By concentrating our resources on profitable activities, scaling back and withdrawing from less attractive activities we have further reduced adjusted EBITDA losses by c60% year over year despite a small decline in headline revenue year over year.
I am especially pleased with the growth and contribution generated from our portfolio of owned brands and am excited about the future potential for these brands. Both Napiers the Herbalists and
The disposal of Probio7 and the addition of Optimised Energetics Ltd leave us with a well-positioned portfolio of high growth, high potential, differentiated owned brands and the addition of vertically integrated manufacturing further strengthens the competitiveness of our platform.
We are clear that our future lies in building a portfolio of high growth, high potential niche health and healing brands and leveraging our resources across these brands as a shared platform for profitable growth. We see lots of opportunity to further expand our brands to new consumers and markets and will increase investment in them selectively as and when funds are available to do so.
The ability to introduce brands to the Chinese consumer will remain an important group capability and a differentiating factor in our platform for brands. As a result of changes in the Chinese market place the balance of risks and rewards of distributing third party brands in
Once our goal of moving the Group into profit is secure we will work on increasing investment behind the scaling of our owned brands and to selectively add to the portfolio in the future through acquisition in terms of brands and additional platform services.
Whilst the underlying value of the Company, in terms of its assets, capabilities and potential, is not currently reflected in the share price, we remain focused on improving the underlying performance of the business, reaching profitability and increasing shareholder value.
Chief Executive Officer
FINANCIAL REVIEW
Overview
Group revenues for the year decreased by 3% to
Revenues in Brand Ownership up 16% to
The Group's gross margin increased to 60% from 55% in FY 2023, driven by increase in revenues from Brand Ownership as a % of total revenue and a change in channel mix.
Operating expenses
Selling and distribution expenses, have increased to 34% (2023: 31%) of revenue, as a result of increasing promotional discounting and competition in
Administrative expenses increased to 48% (2023: 44%) of revenue as the Group has taken a non-cash impairment charge in relation to its Nomad Platform. In addition to the impairment charge, the Group incurred a number of significant non-recurring costs which have been shown separately in the financial statements. These items include redundancy and restructuring costs as a result of the Group's adjustment to its cost base in light of the challenges presented by changing market in
Depreciation and amortisation
The total depreciation and amortisation costs were
Adjusted EBITDA
Adjusted EBITDA means the non-GAAP measure which is defined as Earnings Before Interest, Taxes, Depreciation, and Amortisation and exceptional items. It provides a useful measure of the underlying profitability of the business and is used by management to evaluate the operating performance to make financial, strategic and operating decisions and provides the underlying trends on a comparable basis year on year.
Adjusted EBITDA losses decreased to
|
|
Mar-24 |
Mar-23 |
|
Operation loss |
(4,612,714) |
(4,587,848) |
|
Depreciation and amortisation |
989,208 |
1,140,524 |
|
Share-based payment |
191,800 |
712,271 |
|
Impairment Loss |
2,080,746 |
- |
|
Restructuring costs |
457,594 |
507,085 |
|
Adjusted EBITDA |
(893,366) |
(2,227,968) |
Earnings per share
Basic and diluted loss per share was
Net debt
|
|
Mar-24 |
Mar-23 |
|
Cash and cash equivalents |
867,524 |
2,017,150 |
|
Right-of-use lease liabilities |
(717,400) |
(573,785) |
|
Borrowings |
(1,496,488) |
(1,453,298) |
|
Net debt |
(1,346,364) |
(9,933) |
At the year end, the Group's net debt position was
The decision to stop support for our Nomad Checkout product saw a reduction in cash outflow from investing activities by
Financing costs of
|
|
|
Year ended |
|
Year ended Restated |
|
|
|
£ |
|
£ |
|
Revenue |
|
16,922,669 |
|
17,476,825 |
|
Cost of sales |
|
(6,695,544) |
|
(7,814,362) |
|
Gross profit |
|
10,227,125 |
|
9,662,463 |
|
Selling and distribution expenses |
|
(5,715,219) |
|
(5,381,270) |
|
Administrative expenses |
|
(8,135,412) |
|
(7,728,517) |
|
Adjusted EBITDA* |
|
(893,366) |
|
(2,227,968) |
|
Share-based payment and related expenses |
|
(191,800) |
|
(712,271) |
|
Impairment on intangible assets |
|
(2,080,746) |
|
- |
|
Restructuring costs |
|
(457,594) |
|
(507,085) |
|
EBITDA* |
|
(3,623,506) |
|
(3,447,324) |
|
Depreciation and amortisation |
|
(989,208) |
|
(1,140,524) |
|
Operating loss |
|
(4,612,714) |
|
(4,587,848) |
|
Finance income |
|
6,856 |
|
20 |
|
Finance costs |
|
(261,722) |
|
(162,502) |
|
Loss before taxation |
|
(4,867,580) |
|
(4,750,330) |
|
Taxation |
|
69,520 |
|
150,437 |
|
Loss after taxation |
|
(4,798,060) |
|
(4,599,893) |
|
|
|
|
|
|
|
Other comprehensive income and loss: |
|
|
|
|
|
Exchange differences on translation of foreign operations |
|
(7,227) |
|
(47,859) |
|
Items that may be reclassified to profit and loss in subsequent periods |
|
(7,227) |
|
(47,859) |
|
Total comprehensive loss for the year |
|
(4,805,287) |
|
(4,647,752) |
|
|
|
|
|
|
|
Loss attributable to: |
|
|
|
|
|
Equity holders of the Company |
|
(4,756,999) |
|
(4,550,522) |
|
Non-controlling interests |
|
(41,061) |
|
(49,371) |
|
|
|
(4,798,060) |
|
(4,599,893) |
|
|
|
|
|
|
|
Loss per share (basic and diluted) |
|
(0.0815) |
|
(0.0778) |
|
|
|
|
|
|
|
Comprehensive loss attributable to: |
|
|
|
|
|
Equity holders of the Company |
|
(4,764,226) |
|
(4,598,381) |
|
Non-controlling interests |
|
(41,061) |
|
(49,371) |
|
|
|
(4,805,287) |
|
(4,647,752) |
|
|
|
|
|
Restated |
|
|
|
£ |
|
£ |
|
ASSETS |
|
|
|
|
|
Intangible assets |
|
4,585,661 |
|
7,338,884 |
|
Property, plant and equipment |
|
77,092 |
|
203,417 |
|
Right-of-use assets |
|
688,628 |
|
489,890 |
|
Deferred Tax Asset |
|
179,350 |
|
143,444 |
|
Non-current assets |
|
5,530,731 |
|
8,175,635 |
|
|
|
|
|
|
|
Inventories |
|
2,370,941 |
|
2,212,227 |
|
Trade receivables |
|
1,175,380 |
|
1,722,637 |
|
Corporation tax recoverable |
|
59,376 |
|
227,946 |
|
Other receivables and prepayments |
|
625,248 |
|
706,513 |
|
Cash and cash equivalents |
|
867,524 |
|
2,017,150 |
|
Held for sale |
|
216,597 |
|
- |
|
Current assets |
|
5,315,066 |
|
6,886,473 |
|
|
|
|
|
|
|
Total assets |
|
10,845,797 |
|
15,062,108 |
|
|
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
|
Share capital |
|
583,582 |
|
583,582 |
|
Share premium |
|
22,954,413 |
|
22,954,413 |
|
Merger relief reserve |
|
(2,063,814) |
|
(2,063,814) |
|
Accumulated loss |
|
(17,446,128) |
|
(12,880,929) |
|
Currency translation reserve |
|
(86,587) |
|
(79,360) |
|
Total equity attributable to parent |
|
3,941,466 |
|
8,513,892 |
|
Non-controlling interest |
|
(180,303) |
|
(139,242) |
|
Total equity |
|
3,761,163 |
|
8,374,650 |
|
|
|
|
|
|
|
Right-of-use lease liabilities |
|
617,819 |
|
260,779 |
|
Borrowings |
|
1,434,895 |
|
1,398,787 |
|
Deferred tax liability |
|
492,787 |
|
470,356 |
|
Accrued liabilities |
|
- |
|
512,441 |
|
Total non-current liabilities |
|
2,545,501 |
|
2,642,363 |
|
|
|
|
|
|
|
Trade and other payables |
|
3,897,739 |
|
3,349,144 |
|
Deferred revenue |
|
480,220 |
|
328,434 |
|
Borrowings |
|
61,593 |
|
54,511 |
|
Right-of-use lease liabilities |
|
99,581 |
|
313,006 |
|
Total current liabilities |
|
4,539,133 |
|
4,045,095 |
|
Total liabilities |
|
7,084,634 |
|
6,687,458 |
|
|
|
|
|
|
|
Total liabilities and equity |
|
10,845,797 |
|
15,062,108 |
|
|
Share capital |
|
Share premium |
|
Merger relief reserve |
|
Currency translation reserve |
|
Accumulated loss Restated |
|
Non-controlling interests |
|
Total Equity Restated |
|
|
£ |
|
£ |
|
£ |
|
£ |
|
£ |
|
£ |
|
£ |
|
Balance at |
547,148 |
|
21,022,958 |
|
(2,063,814) |
|
(31,501) |
|
(8,546,753) |
|
(89,871) |
|
10,838,167 |
|
Loss after taxation (restated) |
- |
|
- |
|
- |
|
- |
|
(4,550,522) |
|
(49,371) |
|
(4,599,893) |
|
Other comprehensive loss |
- |
|
- |
|
- |
|
(47,859) |
|
- |
|
- |
|
(47,859) |
|
Total comprehensive loss for the year |
- |
|
- |
|
- |
|
(47,859) |
|
(4,550,522) |
|
(49,371) |
|
(4,647,752) |
|
Shares issued on subscription |
35,976 |
|
1,902,413 |
|
- |
|
- |
|
- |
|
- |
|
1,938,389 |
|
Shares issued on acquisition |
458 |
|
29,042 |
|
- |
|
- |
|
- |
|
- |
|
29,500 |
|
Share based payments |
- |
|
- |
|
- |
|
- |
|
216,346 |
|
- |
|
216,346 |
|
|
36,434 |
|
1,931,455 |
|
- |
|
- |
|
216,346 |
|
- |
|
2,184,235 |
|
Balance at |
583,582 |
|
22,954,413 |
|
(2,063,814) |
|
(79,360) |
|
(12,880,929) |
|
(139,242) |
|
8,374,650 |
|
Loss after taxation |
- |
|
- |
|
- |
|
- |
|
(4,756,999) |
|
(41,061) |
|
(4,798,060) |
|
Other comprehensive loss |
- |
|
- |
|
- |
|
(7,227) |
|
- |
|
- |
|
(7,227) |
|
Total comprehensive loss for the year |
- |
|
- |
|
- |
|
(7,227) |
|
(4,756,999) |
|
(41,061) |
|
(4,805,287) |
|
Share based payments |
- |
|
- |
|
- |
|
- |
|
191,800 |
|
- |
|
191,800 |
|
|
- |
|
- |
|
- |
|
- |
|
191,800 |
|
- |
|
191,800 |
|
Balance at |
583,582 |
|
22,954,413 |
|
(2,063,814) |
|
(86,587) |
|
(17,446,128) |
|
(180,303) |
|
3,761,163 |
|
|
|
|
|
Restated |
|
|
|
£ |
|
£ |
|
Cash flows from operating activities |
|
|
|
|
|
Loss after taxation |
|
(4,798,060) |
|
(4,599,893) |
|
Cash flow from operations reconciliation: |
|
|
|
|
|
Depreciation and amortisation |
|
989,208 |
|
1,140,524 |
|
Impairment of Intangible asset |
|
2,080,746 |
|
- |
|
Finance expense |
|
113,225 |
|
20,630 |
|
Finance income |
|
(6,856) |
|
(20) |
|
Income tax credit |
|
(69,520) |
|
(150,437) |
|
Share based payment |
|
191,800 |
|
216,346 |
|
Working capital adjustments: |
|
|
|
|
|
(Increase)/decrease in inventories |
|
(158,714) |
|
1,508,021 |
|
Decrease in trade and other receivables |
|
628,522 |
|
131,918 |
|
Increase/(decrease) in trade and other payables |
|
187,942 |
|
(626,169) |
|
Cash used in operating activities |
|
(841,707) |
|
(2,359,080) |
|
Taxes received/(paid) |
|
224,615 |
|
(7,477) |
|
Net cash used in operating activities |
|
(617,092) |
|
(2,366,557) |
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
Purchase of property, plant and equipment |
|
(37,484) |
|
(67,602) |
|
Purchase of intangible assets |
|
(220,734) |
|
(1,095,564) |
|
Payment of deferred consideration |
|
- |
|
(80,000) |
|
Disposal of property, plant and equipment |
|
84,206 |
|
9,336 |
|
Disposal of right of use asset |
|
(47,813) |
|
- |
|
Disposal of intangible asset |
|
16,435 |
|
- |
|
Finance income |
|
6,856 |
|
20 |
|
Net cash used in investing activities |
|
(198,534) |
|
(1,233,810) |
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
Proceeds from issue of shares, net of fees |
|
- |
|
1,937,889 |
|
Repayment of right-of-use lease liabilities |
|
(283,218) |
|
(329,001) |
|
Interest paid |
|
(21,717) |
|
(24,671) |
|
Proceeds from other loans |
|
31,363 |
|
- |
|
Repayment of borrowings |
|
(54,857) |
|
(71,131) |
|
Net cash generated used in/(from) financing activities |
|
(328,429) |
|
1,513,086 |
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents |
|
(1,144,055) |
|
(2,087,282) |
|
|
|
|
|
|
|
Cash and cash equivalents - beginning of the year |
|
2,017,150 |
|
4,049,118 |
|
Effects of exchange rate changes on the balance of cash held in foreign currencies |
|
(5,571) |
|
55,314 |
|
Cash and cash equivalents - end of the year |
|
867,524 |
|
2,017,150 |
1. General Information
Samarkand Group plc was incorporated in
Samarkand Group plc's registered office is Unit
The Consolidated Group financial statements represent the consolidated results of Samarkand Group plc and its subsidiaries, (together referred to as the "Group").
2. Basis of preparation and measurement
The financial statements have been prepared in accordance in accordance with
The financial information set out in this document does not constitute the Group's statutory accounts for the year ended
Statutory accounts for the year ended
We draw your attention to the going concern paragraph below, which indicates the key risks and uncertainties which may affect the future prospects and trading activities of the group. The going concern paragraph below indicates that the group's revenue has decreased by 3% against the prior year and that the group continues to be loss making. The group reported an adjusted EBITDA loss of
The independent auditor's reports on the Annual Report and Accounts for the year ended
Going concern
The financial statements have been prepared on a going concern basis, assuming that the Group will continue its operations for the foreseeable future. The Directors have assessed the Company's ability to continue as a going concern, taking into consideration the current economic and market conditions, as well as the Group's financial performance and cash flow projections.
The Group's revenues have decreased by 3% against the prior year and adjusted EBITDA losses have reduced by 60 % against the prior year as a result of material improvements in gross margin, growth in our owned brands and the delivery of operating efficiencies across the business as we continue to focus on profitable growth. Cost reduction initiatives were taken to improve the Group's operating efficiency, it's financial position to mitigate the impact of challenging market conditions in
Despite the progress made, the Group continued to face challenging market conditions in
The Directors recognise the importance of moving the Group into profitability and have made significant progress towards this goal. In addition, the Directors are actively exploring additional funding options to support the Group's operations and long-term viability. In
The Directors continue to consider various options including trade financing, and other strategic opportunities. These efforts are ongoing, and the Directors are diligently working towards these goals.
Despite the cost base reduction and ongoing exploration of additional funding, in the event that trading does not proceed as planned and in conjunction with the loan with Global Smollan Holdings becoming due in
Although there are material uncertainties, several mitigating factors have been considered by the Directors in their assessment of the going concern assumption. These include the steps taken to further reduce costs and the progress made in exploring various strategic options to raise additional funds. The Directors believe that these factors, will enable the Group to overcome the identified challenges and continue its operations.
To address the material uncertainties, the Directors will continue to closely monitor the Group's financial performance, cash flow projections, and market conditions. They will continue to proactively manage the Group's cost base, seeking further efficiencies where possible.
The Directors are confident in the Group's ability to mitigate the identified risks and uncertainties. As a result, the financial statements have been prepared on a going concern basis, acknowledging the material uncertainties that may cast significant doubt on the Group's ability to continue as a going concern.
3. Revenue from contracts with customers
During the year ending
Disaggregation of revenue from contracts with customers:
|
|
|
|
|
|
|
|
|
£ |
|
£ |
|
Revenue analysed by class of business: |
|
|
|
|
|
Brand ownership |
|
7,748,048 |
|
6,678,067 |
|
Brand acceleration |
|
8,204,409 |
|
9,976,116 |
|
Distribution |
|
740,999 |
|
658,538 |
|
Nomad Checkout |
|
149,337 |
|
119,017 |
|
Other |
|
79,876 |
|
45,087 |
|
Total revenue |
|
16,922,669 |
|
17,476,825 |
|
Cost of sales by business unit: |
|
|
|
|
|
Brand ownership |
|
2,772,796 |
|
2,516,506 |
|
Brand acceleration |
|
3,539,317 |
|
4,948,361 |
|
Distribution |
|
351,413 |
|
319,947 |
|
Nomad Checkout |
|
31,707 |
|
26,846 |
|
Other |
|
311 |
|
2,702 |
|
Total costs of sale |
|
6,695,544 |
|
7,814,362 |
4. Intangible assets
|
|
Development costs |
|
Trademarks |
|
Brands |
|
Goodwill |
|
Website |
|
Total |
|
|
£ |
|
£ |
|
£ |
|
£ |
|
£ |
|
£ |
|
Cost |
|
|
|
|
|
|
|
|
|
|
|
|
At 1 April 2022 |
2,330,437 |
|
99,596 |
|
2,484,091 |
|
2,829,718 |
|
70,198 |
|
7,814,040 |
|
Additions |
1,076,159 |
|
18,624 |
|
- |
|
- |
|
782 |
|
1,095,565 |
|
At 31 March 2023 |
3,406,596 |
|
118,220 |
|
2,484,091 |
|
2,829,718 |
|
70,980 |
|
8,909,605 |
|
Additions |
180,832 |
|
17,402 |
|
- |
|
- |
|
22,500 |
|
220,734 |
|
Disposal |
- |
|
- |
|
- |
|
(16,435) |
|
- |
|
(16,435) |
|
Reclassify as held for sale |
- |
|
(70,634) |
|
(459,916) |
|
- |
|
(24,130) |
|
(554,680) |
|
At 31 March 2024 |
3,587,428 |
|
64,988 |
|
2,024,175 |
|
2,813,283 |
|
69,350 |
|
8,559,224 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
|
|
|
|
|
At 1 April 2022 |
493,548 |
|
32,503 |
|
271,680 |
|
- |
|
5,073 |
|
802,804 |
|
Charge for the year |
572,744 |
|
14,108 |
|
161,960 |
|
- |
|
19,105 |
|
767,917 |
|
At 31 March 2023 |
1,066,292 |
|
46,611 |
|
433,640 |
|
- |
|
24,178 |
|
1,570,721 |
|
Charge for the year |
462,365 |
|
16,770 |
|
161,938 |
|
- |
|
19,106 |
|
660,179 |
|
Impairment |
2,058,771 |
|
4,446 |
|
- |
|
10,236 |
|
7,293 |
|
2,080,746 |
|
Reclassify as held for sale |
- |
|
(39,602) |
|
(287,448) |
|
- |
|
(11,033) |
|
(338,083) |
|
At 31 March 2024 |
3,587,428 |
|
28,225 |
|
308,130 |
|
10,236 |
|
39,544 |
|
3,973,563 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book value |
|
|
|
|
|
|
|
|
|
|
|
|
At 31 March 2024 |
- |
|
36,763 |
|
1,716,045 |
|
2,803,047 |
|
29,806 |
|
4,585,661 |
|
At 31 March 2023 |
2,340,304 |
|
71,609 |
|
2,050,451 |
|
2,829,718 |
|
46,802 |
|
7,338,884 |
|
|
|
|
|
|
|
|
|
|
|
|
|
At each reporting date, the Directors assess whether indications exist that an asset may be impaired. If indications do exist, the Directors estimate the asset's recoverable amount. An asset's recoverable amount is the higher of an assets or cash-generating unit's fair value less costs to sell and its value-in-use.
Management have assessed that there are 3 cash generating units, these include Brand Acceleration, Brand Ownership and Distribution. Brand Acceleration encompasses the technology and service solutions designed to provide Clients cross border eCommerce solutions into
Management have performed an impairment review as required by IAS 36 and have concluded, as a result of the decision to stop supporting the Nomad Checkout product and the changing eCommerce market in
The recoverable amount of the assets has been determined from a review of the current and forecasted performance of the cash generating unit through to March 2029. The key assumptions for these calculations are discount rates and revenue growth rates. In preparing these projections, a discount rate of 12% has been used based on the weighted average cost of capital and the perpetual growth rate of 4% has been assumed. Management has also made assumptions around the growth in relation to revenues generated from Brand Ownership Sales. This includes acquiring new customers, increasing the number of sales channels and partners in its distribution network and adjusting its cost base. If management's assumptions with regards to revenue were to change by 1% over the projected period with corresponding change to variable costs, the value in use calculation would result in £881k change for Brand Ownership, in the recoverable amount of the assets. If management's assumptions with regards to discount rate were to change by 1% over the projected period, the value in use calculation would result in a £2m change for Brand Ownership, in the recoverable amount of the asset.
5. Right-of-use assets
|
|
|
|
|
|
|
Land and buildings |
|
|
|
|
|
|
|
|
|
£ |
|
|
|
Cost |
|
|
|
|
|
|
|
|
|
At 1 April 2022 |
|
|
|
|
|
1,362,545 |
|
|
|
Additions |
|
|
|
|
|
155,596 |
|
|
|
At 31 March 2023 |
|
|
|
|
|
1,518,141 |
|
|
|
Additions |
|
|
|
|
|
632,461 |
|
|
|
Disposal |
|
|
|
|
|
(1,362,545) |
|
|
|
At 31 March 2024 |
|
|
|
|
|
788,057 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
|
|
At 1 April 2022 |
|
|
|
|
|
753,910 |
|
|
|
Charge for the year |
|
|
|
|
|
274,341 |
|
|
|
At 31 March 2023 |
|
|
|
|
|
1,028,251 |
|
|
|
Charge for the year |
|
|
|
|
|
250,370 |
|
|
|
Disposal |
|
|
|
|
|
(1,179,192) |
|
|
|
At 31 March 2024 |
|
|
|
|
|
99,429 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book value |
|
|
|
|
|
|
|
|
|
At 31 March 2024 |
|
|
|
|
|
688,628 |
|
|
|
At 31 March 2023 |
|
|
|
|
|
489,890 |
|
|
|
|
|
|
|
|
|
|
|
|
The Group leases land and buildings for its offices and warehouses under agreements of between five to ten years with, in some cases, options to extend and break clauses. The leases have initial rent-free periods and 5 yearly upward only rent reviews. No extension to these leases has been assumed, the impact is not considered material to users of the financial statements.
Future minimum lease payments associated with the land and building leases were as follows:
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
|
£ |
|
£ |
|
Not later than one year |
|
156,430 |
|
328,491 |
|
Later than one year and not later than two years |
|
211,990 |
|
218,190 |
|
Later than two years and not later than five years |
|
452,910 |
|
48,750 |
|
Over five years |
|
78,667 |
|
- |
|
Total minimum lease payments |
|
899,997 |
|
595.431 |
|
|
|
|
|
|
|
Less: future finance charges |
|
(182,597) |
|
(21,646) |
|
Present value of future lease payments |
|
717,400 |
|
573,785 |
|
|
|
|
|
|
|
Current |
|
99,581 |
|
313,006 |
|
Non-current |
|
617,819 |
|
260,779 |
|
Total lease liabilities |
|
717,400 |
|
573,785 |
6. Inventories
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
|
£ |
|
£ |
|
Finished goods |
|
2,770,112 |
|
2,980,627 |
|
Provision for obsolescence |
|
(399,171) |
|
(768,400) |
|
Total inventories |
|
2,370,941 |
|
2,212,227 |
|
|
|
|
|
|
|
Cost of inventory recognised in profit and loss |
|
6,695,544 |
|
7,814,364 |
7. Trade receivables
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
|
£ |
|
£ |
|
Trade receivables |
|
1,325,677 |
|
1,840,464 |
|
Provision for expected credit loss |
|
(150,297) |
|
(117,827) |
|
Total trade receivables |
|
1,175,380 |
|
1,722,637 |
8. Other receivables and prepayments
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
|
£ |
|
£ |
|
Accrued income |
|
15,570 |
|
- |
|
Prepayments |
|
376,981 |
|
423,352 |
|
Other receivables |
|
232,697 |
|
283,161 |
|
Total other receivables and prepayments |
|
625,248 |
|
706,513 |
9. Borrowings
The following table provides a reconciliation of the Group's future maturities of its total borrowings for each of the periods presented:
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
|
£ |
|
£ |
|
Not later than one year: |
|
|
|
|
|
Bank loans |
|
57,043 |
|
54,511 |
|
Other loans |
|
4,550 |
|
- |
|
Current |
|
61,593 |
|
54,511 |
|
|
|
|
|
|
|
Payable after one year but less than five years: |
|
|
|
|
|
Fixed rate secured loan notes |
|
1,366,430 |
|
1,299,746 |
|
Bank loans |
|
41,998 |
|
99,041 |
|
Other loans |
|
26,467 |
|
- |
|
Non-current |
|
1,434,895 |
|
1,398,787 |
|
Total borrowings |
|
1,496,488 |
|
1,453,298 |
10. Trade and other payables
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
|
£ |
|
£ |
|
Trade payables |
|
1,533,882 |
|
1,672,907 |
|
Accrued liabilities |
|
1,928,130 |
|
1,773,483 |
|
Other payables |
|
130,151 |
|
164,199 |
|
Other taxes and social security |
|
305,576 |
|
250,996 |
|
Total |
|
3,897,739 |
|
3,861,585 |
|
|
|
|
|
|
|
Current |
|
3,897,739 |
|
3,349,144 |
|
Non-current |
|
- |
|
512,441 |
|
Total |
|
3,897,739 |
|
3,861,585 |
|
|
|
|
|
|
11. Held for sale
In line with the Directors decision to sell Probio7, the Group has reclassified the non-current assets of Probio7 as held for sale. As at 31 March 2024, the carrying amount of the non-current assets reclassified to held for sale was £216,598. The fair value of the assets was not materially different from the carrying amount at the reporting date.
The reclassification has no impact on profit or loss for the year ended 31 March 2024. The impact of the reclassification on the statement of financial position was as follows:
|
|
|
Before reclassification |
|
After reclassification |
|
Non-current assets |
|
£ |
|
£ |
|
Intangible assets |
|
216,597 |
|
- |
|
|
|
216,597 |
|
- |
|
Current assets |
|
|
|
|
|
Held for sale |
|
- |
|
216,597 |
|
|
|
- |
|
216,597 |
|
|
|
|
|
|
12. Material subsequent events
On 21 May 2024, the Group acquired the entire share capital of Optimised Energetics Ltd for a total consideration of £1.3m, comprising of £650,000 in cash on a cash free debt free basis and deferred consideration of £650,000 payable in cash over a three-year period. The Executive directors provided £400,000 unsecured non-convertible loan to the Company at a rate of 2% above the base rate.
On 13 June 2024, the Group disposed of its probiotic brand Probio7 for a total consideration of £1.3m to be satisfied by initial consideration of £1.1m in cash and deferred consideration of £0.2m payable in equal instalments over a 12-month period. The loans made by the Executive directors were repaid in full.
On 15 July 2024, the Group signed a new trademark license agreement with LG, a skin care and personal care company, which enables LG to use Napiers the Herbalist's trademark and IP for a period five years.
* EBITDA and Adjusted EBITDA are non−GAAP measures used to represent the trading performance and results of the Group. EBITDA is defined as profit or loss before tax adjusted for finance income and expense, depreciation and amortisation. Adjusted EBITDA excludes those items the Group considers to be non−recurring or material in nature that may distort an understanding of financial performance or impair comparability.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE